RenovoRx, Inc. reports news on targeted oncology drug delivery, the commercialization of RenovoCath®, and clinical development of its TAMP™ therapy platform. The company is a life-sciences issuer developing localized cancer therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device used for temporary vessel occlusion and chemotherapeutic drug infusion.
Recurring updates cover RenovoCath adoption at U.S. cancer centers, intellectual-property protection for the device, financing activity, financial results, and presentations of clinical or pharmacologic data. News also tracks IAG, the investigational intra-arterial gemcitabine product candidate delivered via RenovoCath, including disclosures tied to the TIGeR-PaC trial in locally advanced pancreatic cancer and orphan drug designations for pancreatic and bile duct cancer.
RenovoRx (Nasdaq: RNXT) announced full enrollment of its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, evaluating intra-arterial gemcitabine (IAG) delivered via the FDA-cleared RenovoCath device using the TAMP™ platform versus standard intravenous gemcitabine plus Abraxane. Patient enrollment closed as of August 7, 2026.
According to the company, the study’s primary endpoint is overall survival, with trial completion expected in the first half of 2027 after 86 events (patient deaths); 78 events had occurred as of August 11, 2026. Initial topline data are anticipated in the second half of 2027. The trial has passed two independent interim analyses (after the 26th event in 2023 and 52nd in 2025) with recommendations to continue. RenovoRx reported approximately $1.1 million in RenovoCath sales in 2025 and a record $563,000 in Q1 2026, and RenovoCath with gemcitabine has Orphan Drug Designation for pancreatic and bile duct cancer.
RenovoRx (Nasdaq: RNXT) reported the first commercial clinical use of RenovoCath for localized chemotherapy delivery in a sarcoma patient at CARTI Cancer Center in Little Rock. Treatment began in late June 2026 and is ongoing, delivering chemotherapy near the tumor rather than via systemic intravenous infusion.
CARTI is also using RenovoCath in pancreatic cancer, illustrating broader physician-driven use across solid tumors within the device’s FDA-cleared indications. RenovoCath is cleared for isolation of blood flow and localized infusion, including chemotherapeutic drug delivery. According to RenovoRx, 2025 RenovoCath sales were approximately $1.1 million, with a record $563,000 in Q1 2026.
The company continues to commercialize its TAMP therapy platform and evaluate its intra-arterial gemcitabine (IAG) combination product in the ongoing Phase III TIGeR-PaC trial, targeting locally advanced pancreatic cancer. RenovoRx anticipates full enrollment in the near term and a final data readout in mid to late 2027. IAG is investigational and not yet approved for sale but has received FDA Orphan Drug Designation with potential market exclusivity upon any future approval.
RenovoRx (Nasdaq: RNXT) will participate in a JonesTrading virtual key opinion leader webinar, “The Evolving Pancreatic Cancer Landscape: The Role of RenovoRx's TAMP Platform and Emerging Clinical Advances,” on Thursday, August 13, 2026 at 1:30 p.m. ET. The event will feature oncology experts Dae Won Kim, MD (Moffitt Cancer Center), Ravi Shridhar, MD, PhD (AdventHealth Cancer Institute), CEO Shaun Bagai, and moderator Justin Walsh of JonesTrading.
Topics include the pancreatic cancer treatment landscape, RenovoRx’s TAMP™ platform and FDA-cleared RenovoCath® device, the ongoing Phase III TIGeR-PaC trial of intra-arterial gemcitabine, and clinical integration of TAMP. Commercial updates will cover RenovoCath’s stand-alone device launch, 2025 sales of about $1.1 million, record Q1 2026 sales of $563,000, and efforts to expand cancer center customers. A replay and webcast access will be available via RenovoRx’s investor relations site.
RenovoRx (Nasdaq: RNXT) will host its second quarter 2026 financial results and business highlights conference call on Wednesday, August 12, 2026, at 4:30 p.m. ET. Management plans to discuss growing revenues from commercial sales of the FDA-cleared RenovoCath drug-delivery device, expanding adoption at high-volume U.S. cancer centers, and repeat orders from existing customers.
The call will also provide an update on the ongoing Phase III TIGeR-PaC trial of intra-arterial gemcitabine via RenovoCath in locally advanced pancreatic cancer, with full enrollment anticipated in the near term and final data expected in mid-to-late 2027. RenovoRx will highlight progress on its TAMP™ therapy platform, including Orphan Drug Designation for oxaliplatin in pancreatic cancer, support for investigator-initiated trials, and additional indication exploration. The event offers dial-in and webcast access, with a replay available until August 26, 2026.
RenovoRx (Nasdaq: RNXT) announced a peer-reviewed case study from Moffitt Cancer Center describing intra-arterial gemcitabine delivery via its TAMP therapy platform using the FDA-cleared RenovoCath catheter in unresectable locally advanced pancreatic cancer.
PET-CT showed a 52% reduction in tumor metabolic activity after eight TAMP procedures, while CT scans showed stable disease, suggesting PET-CT may better monitor response to TAMP-delivered treatment.
RenovoRx (Nasdaq: RNXT) received FDA Orphan Drug Designation for intra-arterial oxaliplatin to treat pancreatic cancer, its third ODD and second in pancreatic cancer.
Benefits include seven years of potential market exclusivity, a 25% clinical research tax credit, FDA fee waiver, and grant eligibility. The TIGeR-PaC Phase III trial continues, with enrollment closure expected June 2026 and final data in mid–late 2027.
RenovoRx (Nasdaq: RNXT) reported pharmacokinetic and pharmacodynamic data from a sub-study of its ongoing Phase III TIGeR-PaC trial in locally advanced pancreatic cancer, published for the 2026 ASCO Annual Meeting.
The sub-study evaluates the TAMP platform delivering intra-arterial gemcitabine via RenovoCath (IAG) in 16 patients across six sites, suggesting reduced systemic gemcitabine exposure, increased inactive metabolite levels, and a correlation with reduced CA 19-9, potentially supporting higher local potency and fewer systemic side effects versus IV gemcitabine.
RenovoRx (Nasdaq: RNXT) will present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20, 2026. CEO Shaun Bagai and CFO Mark Voll will discuss record Q1 2026 RenovoCath revenue, device adoption, repeat orders, and key clinical programs.
They will review the Phase III TIGeR-PaC trial in locally advanced pancreatic cancer, expected enrollment completion by end of June 2026 and final data mid to late 2027, plus investigator-initiated and registry studies.
RenovoRx (Nasdaq: RNXT) reported record Q1 2026 revenue of $563,000, up 136% quarter-over-quarter and exceeding 50% of full-year 2025 revenue. Active commercial cancer centers increased to 16, with 32 more in the pipeline.
Cash totaled $12.4 million, supported by a $10 million private placement, which the company believes funds operations into at least the second half of 2027. The Phase III TIGeR-PaC trial is 93% enrolled, with full enrollment expected by June 2026 and final data anticipated in mid to late 2027. Net loss was $3.5 million, and RenovoRx reiterated 2026 revenue guidance of $3–$4 million.
RenovoRx (Nasdaq: RNXT) will host its First Quarter 2026 financial results and business highlights conference call on May 14, 2026 at 4:30 pm ET. Management will discuss commercial momentum for RenovoCath, repeat orders, and updates on the Phase III TIGeR-PaC trial nearing full enrollment and on track for completion in H1 2026.
A replay will be available through May 28, 2026, and webcast details are on the company's Investor Relations site.